1.
Bioorg Med Chem Lett
; 17(19): 5300-9, 2007 Oct 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17761416
RESUMO
This communication highlights the development of a nicotinamide series of histone deacetylase inhibitors within the benzamide structural class. Extensive exploration around the nicotinamide core led to the discovery of a class I selective HDAC inhibitor that possesses excellent intrinsic and cell-based potency, acceptable ancillary pharmacology, favorable pharmacokinetics, sustained pharmacodynamics in vitro, and achieves in vivo efficacy in an HCT116 xenograft model.